About Ovid Therapeutics Inc.
From Ovid: Ovid Therapeutics Inc. is a New York-based biopharmaceutical company using its BoldMedicine® approach to develop medicines that transform the lives of patients with rare neurological disorders. Ovid has a broad pipeline of potential first-in-class medicines in development.
From clinical potential to meaningful therapies—Ovid Therapeutics is developing lifechanging therapies based on our deep understanding of key biological pathways and their central role in rare neurological diseases. We seek to develop medicines using novel and clinically relevant endpoints, to capture the real-world ways patients benefit from addressing underlying disorder pathology.
In 2020, Ovid launched a partnership with the Chung Lab to identify, develop and advance new treatments into future clinical trials for both KAND and other rare conditions. This collaboration strategically approaches research to identify molecular targets for advancing the development of genetic-based therapies.
